Actively Recruiting
Study to Find the Best Length of PD-1 Immunotherapy Before Surgery in Stage II-III dMMR Rectal Cancer A Prospective Multicenter Single-Group Study
Led by Xijing Hospital · Updated on 2024-12-27
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating the optimal number of cycles of PD-1 monotherapy needed to achieve a pathological complete response pCR in patients with stage II-III dMMRMSI-H rectal cancer. The study aims to ensure effective treatment while comparing pathological response rates, side effects, and three-year event-free survival among different treatment durations. Participants will receive preoperative PD-1 antibody monotherapy and undergo reassessment every two cycles. If a clinical complete response cCR is observed, surgery will be performed. The study is a prospective, multicenter, single-arm observational trial assessing the effects of varying treatment cycles. During the study, participants will be closely monitored through regular assessments to track treatment response and adverse reactions. Researchers will evaluate pathological complete response rates and three-year event-free survival. The study expects to follow participants until September 2028, with ongoing observation of outcomes and safety.
CONDITIONS
Brief Title
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
Research Team
J
Jipeng Li, Doctor
Y
Yihuan Qiao, Doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
